同类氨酸诱导大脑和视网膜微血管内皮细胞屏障损伤和通过NLRP3炎症酶途径通过差异性超透性
O'lisa Yaa Waithe1, Aliyah Anderson1, Saravanakumar Muthusamy1
1Department of Surgery and Neuroscience Institute, Morehouse School of Medicine, Atlanta, Georgia, USA.
Microcirculation (New York, N.Y. : 1994)
|July 17, 2025
概括
同类氨酸 (HCY) 增加了血视网膜和血脑屏障的透性. NLRP3炎症体起着作用,特别是在大脑内皮细胞中,这表明SANS等疾病的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 血管生物学 血管生物学
背景情况:
- 同型氨酸 (HCY) 与神经眼综合征 (如SANS) 有关.
- 血视网膜屏障 (BRB) 和血脑屏障 (BBB) 功能障碍是SANS的关键.
- 在SANS病理生物学中HCY和NLRP3炎症酶的作用需要研究.
研究的目的:
- 为了研究同类氨酸 (HCY) 如何影响BRB和BBB的透性.
- 确定NLRP3炎症酶在HCY诱导的屏障功能障碍中的作用.
- 评估SANS.的潜在治疗点.
主要方法:
- 人类大脑和视网膜的微血管内皮细胞 (HBMEC和HRMEC) 用HCY进行治疗.
- 用NLRP3炎症酶抑制剂MCC950来评估其调节作用.
- 试验包括细胞活力,酶-1活性,ZO-1表达和屏障透性.
主要成果:
- 在视网膜和大脑内皮细胞中,HCY显著增加了超透性.
- 在大脑内皮细胞中,MCC950减弱了HCY诱导的超透性.
- HCY增加了caspase-1活性,并改变了紧结蛋白ZO-1的表达.
结论:
- 在视网膜和大脑内皮细胞中,HCY诱导了超透性.
- 在脑内皮细胞中,NLRP3炎症酶介导的效应更为明显.
- 这些发现突显了HCY和NLRP3在SANS相关的屏障功能障碍中的参与.
相关概念视频
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
751
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
751
01:29Hepatic Encephalopathy
33
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
33